Skip to main content
Premium Trial:

Request an Annual Quote

Transnetyx Acquires Sequencing, Genotypic Services Firm Laragen

NEW YORK — Transnetyx said on Tuesday that it has acquired sequencing and genotyping services firm Laragen.

Financial terms of the transaction were not disclosed.

Based in Culver City, California, Laragen offers a range of services to academic and industry customers including Sanger sequencing, mouse genotyping, Illumina MiSeq sequencing, cell line and microbial identification, and fragment analysis. Transnetyx said the acquisition will help expand its current suite of offerings, which includes automated genotyping, microbiome analysis, and fresh rodent tissue samples.

"Transnetyx has built highly accurate, automated testing solutions and a cohesive distribution network, which will allow us to provide researchers unparalleled access to Laragen's enhanced sequencing services," Transnetyx CEO Bob Bean said in a statement.

In early 2021, Memphis, Tennessee-based Transnetyx — which was acquired by Thompson Street Capital in 2018 — began working with One Codex to offer end-to-end microbiome sequencing and analysis services for human and mouse samples.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.